{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-452706","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-11-09T13:04:59+00:00","discovered_at":"2026-11-09T13:10:00.340491+00:00","generated_at":"2026-11-09T13:10:37.336381+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mentari Therapeutics closes InMed merger, raises $490M; MTRI begins Nasdaq trading Nov 9","bullets":["Merger with InMed Pharmaceuticals completed; combined company is Mentari Therapeutics, trading on the Nasdaq Capital Market under ticker MTRI from Nov 9, 2026.","Private financings totaled ~$490M gross, led by Fairmount, with Venrock, Blackstone, RTW, Wellington, a16z Bio + Health and others; includes conversion of $50.0M of convertible notes.","~58.3M shares and common stock equivalents outstanding after reverse split, financings and merger (excluding equity awards); proceeds fund runway into 2029 and beyond.","MT-001 anti-PACAP monoclonal antibody in Phase 1 with initial data expected mid-2027; MT-002 PACAP/CGRP bispecific on track for regulatory filing Q1 2027, data by year-end 2027.","Greg Divis is CEO of the combined company; Todd Shegog appointed to the board as Audit Committee chair in connection with the closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-452706","json":"https://secwatch.observer/filing/0001193125-26-452706.json","markdown":"https://secwatch.observer/filing/0001193125-26-452706.md","text":"https://secwatch.observer/filing/0001193125-26-452706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/0001193125-26-452706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/d183007d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-09T13:10:37.336381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}